Left Atrial Appendage Closure Device Market Size, Share & Trends Analysis | Global | 2026-2032 | Includes: Endocardial, Epicardial, and 1 Other Device Market

Global Left Atrial Appendage Closure Device Market Report to 2032

The global left atrial appendage closure device market was valued at $2.3 billion in 2025. It is expected to grow at a compound annual growth rate (CAGR) of 10.5%, reaching $4.6 billion by 2032.

This report covers the global market for left atrial appendage (LAA) closure devices, including endocardial and epicardial LAA closure technologies.

The analysis includes unit sales, average selling prices (ASPs), procedure numbers, market size, market shares, growth trends, market forecasts through 2032, and historical data back to 2022.

Market growth is supported by increasing awareness of LAA-related clot risk, improved identification of atrial fibrillation patients at risk of thromboembolic events, and broader adoption of device-based LAA closure. However, procedure complexity and operator dependency continue to limit adoption in lower-volume centers and emerging healthcare markets.

Market Overview

The global left atrial appendage closure device market includes devices used to close or exclude the left atrial appendage, a small pouch in the left atrium associated with thrombus formation in patients with atrial fibrillation.

LAA closure is used to reduce the risk of thromboembolic events in selected patients. These devices are especially relevant for patients with atrial fibrillation who are at elevated stroke risk and may not be ideal candidates for long-term anticoagulation therapy.

The market includes endocardial and epicardial devices. Endocardial devices are placed from inside the heart through a catheter-based approach, while epicardial devices close or exclude the appendage from the outside of the heart.

Growth in the LAA closure device market is supported by improved identification of patients with atrial fibrillation who are at risk of clot formation in the left atrial appendage. While both endocardial and epicardial devices are expected to see increased utilization, endocardial LAA closure devices are expected to account for the majority of market growth due to broader adoption and less invasive procedural approaches.

Market Drivers

LAA Awareness

Increasing awareness of the left atrial appendage and its role in thromboembolic risk is a major driver of the LAA closure device market. As more procedures are performed, awareness of LAA management and the available treatment options is expected to rise.

The WATCHMAN(TM) device helped generate positive publicity for LAA occlusion and increased awareness among physicians, hospitals, and patients. This awareness is expected to benefit all LAA closure devices with clinical data supporting their effectiveness.

As general awareness increases, more patients with atrial fibrillation may be evaluated for device-based LAA closure. This is expected to raise unit sales and apply upward pressure on the value of the global LAA closure device market.

Improved Identification of At-Risk Patients

Improved identification of atrial fibrillation patients at risk of thromboembolic events is supporting market growth. As clinicians better understand LAA-related clot risk, more patients are being evaluated for closure.

This is especially important for patients who cannot tolerate long-term anticoagulation or who face elevated bleeding risk. For these patients, LAA closure can offer a device-based alternative for stroke risk reduction.

Better patient identification is expected to increase procedural volumes over the forecast period. As referral pathways improve and more heart teams evaluate LAA closure candidates, the market is expected to expand steadily through 2032.

Endocardial Device Adoption

Endocardial LAA closure devices are expected to account for most market growth. These devices are placed through a catheter-based approach and are generally less invasive than surgical or epicardial alternatives.

The less invasive nature of endocardial closure supports broader physician and hospital adoption. It also aligns with wider cardiovascular trends favoring catheter-based treatment when clinically appropriate.

As endocardial devices gain regulatory approvals, clinical evidence, and physician familiarity, their utilization is expected to increase. This will support the majority of growth in the global LAA closure device market.

Market Limiters

Procedure Complexity and Operator Dependency

Both endocardial and epicardial LAA closure procedures require specialized training and experienced operators. This limits adoption in lower-volume centers and emerging healthcare markets.

Endocardial procedures require advanced imaging, transseptal access, careful device sizing, and precise placement. Epicardial approaches also require procedural expertise and may involve more complex access or surgical coordination.

Because of this operator dependency, adoption is strongest in experienced centers with established structural heart or electrophysiology programs. The need for training and procedural infrastructure will continue to limit broader use.

Advanced Imaging and Multidisciplinary Requirements

LAA closure procedures often require advanced imaging and multidisciplinary heart team support. Imaging is needed to assess appendage anatomy, guide device placement, and confirm closure success.

This creates barriers for hospitals that do not have the required equipment, staff, or procedural coordination. In some regions, limited imaging access or specialist availability may slow adoption.

The need for a coordinated care pathway can also reduce procedure volumes in smaller facilities. Until more centers build the necessary infrastructure, adoption will remain concentrated in higher-volume programs.

Competitive and Reimbursement Pressure

As more LAA closure devices enter the market, competition is expected to increase. While this can support innovation and wider availability, it may also place pressure on ASPs over time.

Reimbursement conditions can also affect adoption. Hospitals must evaluate whether LAA closure procedures are supported by clear payment pathways and whether the economic value is strong enough to justify program expansion.

These factors may slow adoption in cost-sensitive healthcare systems, especially where clinical evidence, reimbursement, or referral pathways are still developing.

Market Coverage and Data Scope

• Quantitative coverage: Market size, market shares, procedure numbers, market forecasts, market growth rates, units sold, and average selling prices.
• Qualitative coverage: Market drivers and limiters, competitive analysis, recent mergers and acquisitions, company profiles, product portfolios, and leading competitors.
• Time frame: Base year 2025, forecasts to 2032, and historical data back to 2022.
• Market modeling: Revenue is analyzed using unit sales and ASPs, supported by procedure numbers, competitive share analysis, and forecast assumptions.
• Device scope: The report covers left atrial appendage closure devices used to reduce thromboembolic risk, including endocardial, epicardial clip, and epicardial suture LAA devices.

Markets Covered and Segmentation

Left Atrial Appendage Closure Device Market

• Device type: Endocardial, epicardial clip, and epicardial suture LAA devices.

Endocardial LAA closure devices are placed from inside the heart through a catheter-based approach. These devices are expected to account for the majority of market growth due to broader adoption, less invasive delivery, and strong clinical awareness.

Epicardial clip devices close or exclude the left atrial appendage from the outside of the heart. These products are often used during surgical procedures or in settings where an external closure approach is preferred.

Epicardial suture LAA devices use suture-based methods to close the appendage. These devices represent another approach to LAA management and are included within the broader device market.

Each segment is analyzed by market size, market shares, procedure numbers, market forecasts, market growth rates, units sold, and average selling prices.

This segmentation helps manufacturers, investors, and strategy teams understand how procedural approach, physician adoption, patient selection, and device type are shaping the global LAA closure device market.

Competitive Analysis

Boston Scientific was the leader of the global LAA closure device market in 2025. The company offers the WATCHMAN(TM) LAA closure devices as an endocardial option.

Boston Scientific accounts for the majority of the market, supported by broad adoption of WATCHMAN(TM) and strong physician familiarity. However, once additional endocardial devices receive regulatory approval, the company is expected to lose some share to new entrants.

Abbott was the second-leading competitor in the global LAA market in 2025. The company offers the Amplatzer(TM) Amulet(TM) LAA Occluder as an endocardial LAA device.

Abbott is expected to grow its market share in the coming years due to the established use of the Amplatzer(TM) line and broader adoption of Amulet(TM). Its structural heart and closure device experience support its ability to compete in the endocardial LAA segment.

AtriCure was the third-leading competitor in the global LAA market in 2025. The company offers the AtriClip(R) product line as its epicardial option. The AtriClip(R) line includes multiple devices, giving the company an expansive portfolio within epicardial LAA closure. Because of this product breadth, AtriCure is expected to maintain its market share over the coming years.

Technology and Practice Trends

Endocardial LAA Closure

Endocardial LAA closure is expected to remain the largest source of market growth. These devices are delivered through catheter-based procedures and are less invasive than surgical alternatives.

This approach aligns with broader cardiovascular trends favoring minimally invasive structural heart interventions.

Epicardial Clip Closure

Epicardial clip closure remains an important option, especially in surgical settings. AtriCure's AtriClip(R) portfolio is a key example of this approach.

Epicardial closure may be used when external exclusion of the appendage is clinically preferred or when the patient is already undergoing a cardiac surgical procedure.

Epicardial Suture Closure

Epicardial suture-based devices represent another approach to LAA management. These technologies are included within the broader market because they offer a device-based method of appendage closure.

Their role depends on physician preference, procedural setting, and patient anatomy.

AFib Patient Identification

Improved identification of atrial fibrillation patients at risk of LAA-related thromboembolic events is supporting procedure growth.

As screening, referral pathways, and clinical awareness improve, more patients may be evaluated for LAA closure.

Operator Training

LAA closure requires trained operators and experienced teams. Procedure growth depends on the expansion of physician training, imaging expertise, and multidisciplinary support.

Training will remain important as more centers adopt LAA closure programs.

New Entrant Competition

The LAA closure market is expected to become more competitive as more endocardial devices gain regulatory approval. This may support innovation and broader access but could pressure ASPs and reduce share concentration.

Companies with strong clinical data, physician training programs, and broad distribution are expected to remain best positioned.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Why This Report

• How large is the global left atrial appendage closure device market today, and how much is it expected to grow through 2032?
• How are unit sales, procedure numbers, ASPs, and market values changing over time?
• What role does LAA closure play in reducing thromboembolic risk among atrial fibrillation patients?
• How is awareness of LAA-related clot risk affecting procedure volumes?
• Why are endocardial LAA closure devices expected to account for most market growth?
• How do endocardial, epicardial clip, and epicardial suture devices differ?
• What barriers are created by procedure complexity and operator dependency?
• How do imaging requirements and multidisciplinary care teams affect adoption?
• Which companies lead the global LAA closure device market?
• How are Boston Scientific, Abbott, and AtriCure positioned in the competitive landscape?

The Global Left Atrial Appendage Closure Device Market Report from iData Research answers these questions with device-level analysis, procedure-based modeling, ASP data, company share insights, and forecasts through 2032. Use it to evaluate demand, benchmark competitors, understand LAA closure trends, and support commercial planning in the global LAA closure device market.